Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients

Inclusion Criteria: * Cytological and histological confirmation of non-small cell lung cancer (NSCLC) diagnosis, single sputum cytology diagnosis is not accepted * Expected survival period is more than 3 months * Enough blood function reservation: absolute neutrophil count (ANC) 2 x 10E9/L or higher;platelet count 100 x 109 /L or higher;hemoglobin 9 g/dL or higher. * Enough liver function reservation:the total bilirubin less than upper limit of normal;AST and ALT acuities were less than 2.5 times the upper limit of normal (ULN);Alkaline phosphatase 5 times the upper limit of normal (ULN) or less. * Clinical doctors identify patients suitable for standard doses of ganglioside drug therapy, and expected time of medication is at least six weeks * Within 4 weeks before treatment, did not receive other adverse reaction of drugs may cause similar neurotoxicity; 18 weeks before, did not received platinum-based drugs chemical treatment. * No more than 1 degree of the peripheral nervous system diseases exists before enrollment, also no other symptom or disease could affect the adverse reactions of neurotoxicity pathological. * Can't accept other adverse reactions may prevent neurotoxicity treatment or care after enrollment. * Sign the informed consent form. Exclusion Criteria: * Patients with poor general condition, PS score more than 2 points * Women in pregnancy or lactation * Patients (male or female) have fertility possibility but not willing to or not to adopt effective contraception * With other neurological dysfunction which can cause inaccurate record of the occurrence of neurotoxicity and severity * Known or assignment of any of these products to test drugs allergic agent composition * Doctors think inappropriate for patients with ganglioside medication or estimated time of less than 6 weeks * Active infection (determined by the researcher) * According to the researcher's judgment, there is serious disease to endanger the safety of patients, or may prevent the patients from completing the study * Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia